- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT02599974
PET-CT in the Initial Staging of Breast Cancer and in the Early Assessment of Response to Neoadjuvant Chemotherapy (ASAINT)
Role of Fluorodeoxyglucose (FDG) PET-CT in the Initial Staging of Breast Cancer (ASAINT 1) and in the Early Assessment of Response to Neoadjuvant Chemotherapy (ASAINT 2)
The two main objectives of this prospective study are:
- to identify those patients for whom pre-treatment FDG (Fluorodeoxyglucose) PET (positron emission tomography) CT-scan (Computed tomography scan) provides useful information for the treatment of breast cancer (ASAINT 1),
- to improve FDG PET-CT-scan imaging criteria for assessing response to neoadjuvant therapy early, in M0-patients (ASAINT 2).
The secondary objective is to better understand the interactions between the imaging parameters of FDG PET-CT-scan and biological and histological features of breast cancer .
This is a non-interventional study. Two PET-CT-scans are performed, one before starting treatment, and the other after 2 cycles of neoadjuvant chemotherapy. The two PET-CT-scans are prescribed by oncologists from the center of breast diseases Unit at St. Louis hospital, in Paris, France. Oncologists provide clear information to the patients on the purpose of the examination. The examinations are performed in the nuclear medicine department at St. Louis hospital. PET-CT-scans data, tumor characteristics, results of other imaging and biological tests, results of surgery and patient's follow-up are summarized in a "de-identified" file. This file has been declared to the National Commission on Informatics and Liberties (CNIL). The data in this file are established prospectively and secondary analyzed to assess the precise role of PET-CT-scans in the initial staging of breast cancer and to determine the optimal PET-CT-scans criteria to evaluate response to neoadjuvant treatment early.
Aperçu de l'étude
Statut
Les conditions
Type d'étude
Inscription (Anticipé)
Contacts et emplacements
Lieux d'étude
-
-
-
Paris, France, 75010
- Recrutement
- Hopital Siant-louis
-
Contact:
- David Groheux, MD-PHD
- Numéro de téléphone: +33 630603009
- E-mail: david.groheux@aphp.fr
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
Méthode d'échantillonnage
Population étudiée
La description
Inclusion Criteria :
- Histologically confirmed breast cancer
- Stage II and III breast cancer
- Neo-adjuvant chemotherapy
- Baseline PET-CT-scan (ASAINT 1 and 2)
- PET-CT-scans after second cycle of neo-adjuvant chemotherapy (ASAINT 2)
- Tumor biopsy for diagnosis and biological analysis with hormone receptors and Human Epidermal Growth Factor Receptor-2 (HER2) available
- Surgical intervention after completion of neo-adjuvant chemotherapy
- Evaluable pathological response
Exclusion Criteria :
- Other tumor localization
- Non controlled diabetes mellitus
- Pregnancy
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Pathological complete response in M0 patients at baseline PET (stage II-III)
Délai: 18 weeks
|
Absence of residual cancer cells in the primary breast tumor and in axillary lymph nodes
|
18 weeks
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Number of distant metastases (M1 patients at baseline PET)
Délai: 2 weeks
|
Detection of distant metastases by FDG PET-CT
|
2 weeks
|
|
Number of metastatic nodes at baseline PET (axillary and extra-axillary)
Délai: 2 weeks
|
Detection of metastatic axillary and extra-axillary nodes by FDG PET-CT
|
2 weeks
|
|
Standard uptake value on the FDG-PET (Fluorodeoxyglucose positron emission tomography)
Délai: 2 weeks
|
2 weeks
|
|
|
Patients overall survival
Délai: 5 years
|
5 years
|
|
|
event free survival
Délai: 5 years
|
5 years
|
|
|
Patients overall survival
Délai: 3 years
|
3 years
|
|
|
survie sans événement
Délai: 3 ans
|
3 ans
|
|
|
Patients overall survival
Délai: 2 years
|
2 years
|
|
|
event free survival
Délai: 2 years
|
2 years
|
|
|
Total lesion glycolysis on the FDG-PET (Fluorodeoxyglucose positron emission tomography)
Délai: 2 weeks
|
2 weeks
|
|
|
Metabolic tumor volume on the FDG-PET (Fluorodeoxyglucose positron emission tomography)
Délai: 2 weeks
|
2 weeks
|
|
|
Tumor heterogeneity determined on the FDG-PET (Fluorodeoxyglucose positron emission tomography)
Délai: 2 weeks
|
2 weeks
|
Collaborateurs et enquêteurs
Parrainer
Les enquêteurs
- Chercheur principal: David Groheux, MD-PhD, APHP, IUH, University Paris Diderot, Paris 7, SPC
- Chaise d'étude: Matthieu Resche-Rigon, MD-PHD, DRCD APHP Paris
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude
Achèvement primaire (Anticipé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Estimation)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Estimation)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- NI 12020 ASAINT
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .